<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067310</url>
  </required_header>
  <id_info>
    <org_study_id>PROT</org_study_id>
    <nct_id>NCT04067310</nct_id>
  </id_info>
  <brief_title>Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.</brief_title>
  <official_title>Randomized, Open-label Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis in Patients With Anal and Rectal Canal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancer, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancer, Brazil</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-institution trial designed to evaluate the
      effectiveness of a spray skin protector in preventing moist desquamation caused by
      radiotherapy treatment.

      This technology, spray skin protection, depending on the manufacturer, is primarily intended
      to prevent or reduce contact dermatitis. However, this study will be evaluated for use in
      preventing mois desquamation caused by ionizing radiation. The comparing agent will be a
      moisturizer containing in its composition calendula officinalis, agreed upon at the local
      Institution of the study for use in the prevention of radiodermatitis. As secondary
      objectives: describe adverse events, diarrhea, pain and pruritus.

      The study will be conducted at the radiotherapy outpatient clinic of the Cancer Hospital I
      (HCI) of National Cancer Institute (INCA) in Brazil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypotheses are:

      Null (Ho): The incidence of moist desquamation with the spray skin protector is greater than
      or equal to the incidence of moist desquamation in the control group.

      Alternative (H1): The incidence of moist desquamation with the spray skin protector is lower
      than the incidence of moist desquamation in the control group.

      The skin evaluation of the participants will be weekly, with blinding of this professional.
      For the assessment of secondary objectives, adverse events will be applied to the diarrhea
      assessment scales of Radiation Therapy Oncology Group (RTOG) and CTCAE version 5.0; for
      pruritus the CTCAE scale; for pain the Analog Visual Scale (VAS) and the burning or burning
      sensation will only be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 16, 2020</start_date>
  <completion_date type="Anticipated">February 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Moist desquamation incidence</measure>
    <time_frame>from the first day of radiotherapy up to eight weeks</time_frame>
    <description>Moist desquamation incidence after the beginning of radiotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from the first day of radiotherapy up to eight weeks</time_frame>
    <description>Occurrence of adverse events after the beginning of radiotherapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Radiodermatitis</condition>
  <condition>Injury, Radiation</condition>
  <arm_group>
    <arm_group_label>Group Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who will use the spray skin protector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who will use moisturizer containing in its composition calendula officinalis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spray skin protector</intervention_name>
    <description>Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.</description>
    <arm_group_label>Group Experimental</arm_group_label>
    <other_name>barrier film to prevent radiodermatitis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>moisturizer containing in its composition calendula officinalis</intervention_name>
    <description>Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.</description>
    <arm_group_label>Group control</arm_group_label>
    <other_name>conventional treatment to prevent radiodermatitis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients with curative indication and conventional linear accelerator
        treatment planning; no previous history of radiotherapy in the same field / place of
        treatment.

        -

        Exclusion Criteria:patients with pre-existing irradiated dermatitis, visible tumoral lesion
        at the beginning of treatment, previous report of allergic reaction to any products used in
        the research.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabiana V Sim천es, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Escola de Enfermagem Anna Nery (EEAN/UFRJ)/ Instituto Nacional de C창ncer (INCA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabiana V Sim천es, MD</last_name>
    <phone>00552132071596</phone>
    <email>fsimoes@inca.gov.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafael C Silva, PhD</last_name>
    <phone>00552139380948</phone>
    <email>rafaenfer@yahoo.com.br</email>
  </overall_contact_backup>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Cancer, Brazil</investigator_affiliation>
    <investigator_full_name>Fabiana Verdan Sim천es</investigator_full_name>
    <investigator_title>Principal Research Nurse</investigator_title>
  </responsible_party>
  <keyword>barrier film</keyword>
  <keyword>spray skin protection</keyword>
  <keyword>liquid-film</keyword>
  <keyword>barrier product</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiodermatitis</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

